Consumer Defensive · Household & Personal Products · Synthos Deep Dive · 2026-07-03
| Verdict | Hold — systematic Synthos tier |
| Price (2026-07-02) | $95.13 · market cap ~$76.1B |
| Synthos scores (0–10) | Downside Risk 5 · Growth Quality 5 · Exponential Potential 2 |
| Synthos fair value (base case) | ~$92 → −2% · full range $72 (bear) – $112 (bull) |
| Street consensus | $96 target (high $102 / low $79; 19 Buy · 24 Hold · 2 Sell → Hold) — context, not our anchor |
| Valuation | 37× trailing EPS · 25× FY26E · 24× FY27E · 20× FY30E · EV/S 4.0× · EV/EBITDA 21× |
| Exponential Potential | 2/10 · Low — ~4% forward revenue CAGR, ~5–6% EPS CAGR, decelerating category growth; a mature staple, not a grower |
| Technicals | Uptrend but overbought — $95.13, −4% off 52-wk high, above 50/200-DMA, RSI 72, +3.4% 12-mo (SPY +20.6%) |
| Conviction | Low — 0 expert voices in the Synthos KB; fundamentals/quant call only |
| Position sizing | Defensive ballast only, ~1–3% if owned for yield/stability, not for growth |
| Next catalyst | 2026-07-31 Q2'26 earnings (Street EPS $0.95, rev ~$5.36B) |
| Single biggest risk | Paying a premium multiple (37× trailing) for ~4% growth — multiple de-rating if growth stalls |
One-line thesis. Colgate is one of the highest-quality consumer-staples franchises on earth — 41% global toothpaste share, ~60% gross margins, 30%+ return on invested capital, a 0.32 beta — but at 37× trailing / ~24× forward earnings for roughly 4% revenue and 5–6% EPS growth, the price already reflects the quality. A superb business at a full price: own it for ballast, not upside — Watch.
Colgate-Palmolive makes the everyday stuff in your bathroom and under your sink: Colgate toothpaste, Palmolive and Irish Spring soap, Speed Stick deodorant, Fabuloso and Ajax cleaners, plus Hill's pet food. People buy these in good times and bad, which makes the business extremely steady and the stock unusually calm — it barely moves compared to the overall market.
The catch: the stock is expensive for how slowly the company grows. You're paying about $37 for every $1 of last year's profit, but profit is only creeping up a few percent a year. That's a lot to pay for a slow-and-steady grower. Our verdict is Watch — a great company, but the current price doesn't leave much room to make money from here.
Here's what our three scores mean in everyday terms:
The one big worry: you're paying a premium price for a company that grows about as fast as the economy. If growth stalls or the market decides staples are too pricey, the stock can drift down even if the business is fine.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 66.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Solid = CL · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
Colgate-Palmolive (NYSE: CL) is a ~220-year-old (founded 1806) global consumer-products company selling in more than 200 countries. It runs two reporting segments: Oral, Personal and Home Care (toothpaste, toothbrushes, mouthwash, soaps, shower gels, shampoos, deodorants, skin health, dish and fabric care, household cleaners) and Pet Nutrition (Hill's Science Diet and Hill's Prescription Diet). Brands include Colgate, Palmolive, Irish Spring, Softsoap, Speed Stick, Lady Speed Stick, Ajax, Fabuloso, Suavitel, Tom's of Maine, Sanex, EltaMD, PCA SKIN, Filorga and Hill's. CEO Noel Wallace. Fiscal year ends December 31.
Revenue mix (FY2025, from filings):
The strategic frame management keeps returning to is its "2030 strategy": consistent, compounded EPS growth driven by premiumization (higher-value oral and skin-health SKUs), Hill's pet expansion, and a multi-year Strategic Growth and Productivity Program (SGPP) cost initiative (see §9).
There is no expert coverage of Colgate-Palmolive in the Synthos knowledge base. total_claims = 0; there are zero net-bullish and zero cautionary voices on file. This is not an oversight to paper over — the KB skews toward high-conviction growth, tech, and healthcare names, and a mature consumer staple like CL simply hasn't drawn distilled expert commentary in our tracked panel.
What that means for this note: the verdict below is fundamentals- and quant-driven only. There is no conviction premium and no conviction discount — every judgment rests on the reported financials, the live analyst estimates, and the valuation math, all of which are shown transparently. Where the Street has a view, we cite it as context (consensus Hold, $96 target), not as our anchor. No claim_id values are cited anywhere in this note because none exist in the KB for CL; fabricating them would violate the house standard.
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 5 · Moderate | Beta 0.32 and net-debt/EBITDA 1.7× make it about as defensive as equities get, and max drawdown was only −12.5%. But 37× trailing / ~24× forward for ~4% growth is rich, and near-zero GAAP book equity (huge buyback treasury stock) flatters ROE optically. Valuation is the risk, not the business. |
| Growth Quality | 5 · Good | Elite quality — 60% gross margin, ~30% ROIC, 41% global toothpaste share, strong FCF conversion. But growth is pedestrian: ~4% forward revenue CAGR, ~5–6% EPS CAGR, with FY25 organic growth already slowing. Quality without much growth caps this at mid-scale. |
| Exponential Potential | 2 · Low | A mature, slow-compounding staple. Category growth is decelerating (management's own words), there's no TAM re-rating, and at $76B cap in a low-single-digit category there is no multibagger path. Honest score: low. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Organic growth re-accelerates to the high end (4%+), Hill's pet keeps premiumizing, SGPP savings drop through, FX turns tailwind. FY27E EPS beats toward ~$4.20; market keeps paying a premium ~27×. | ~$112 (+18%) |
| Base (our anchor) | Estimates roughly hit — FY27E EPS ~$4.03; a durable ~4% grower with elite margins holds a ~23× multiple. | ~$92 (−2%) |
| Bear | Category growth stalls, private-label/GLP-1-driven consumption shifts bite, FX headwind, staples de-rate. FY27E EPS ~$3.80; multiple compresses to ~19×. | ~$72 (−24%) |
Synthos fair value = the base case, ~$92 (−2%), with the full $72–$112 span as the honest range. This anchor sits just below the Street's $96 consensus and near its $99.5 median — we are slightly less constructive because at 37× trailing the stock already discounts the quality, and 24× forward for ~4% growth is a demanding entry. This is a tracked call — the Forecaster Scorecard grades it once it matures.
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). CL is a high-quality compounder with essentially no exponential characteristics:
Exponential Potential: Low (2/10). Own CL for defensive ballast, dividend, and low volatility, never for exponential upside. This honest framing is why CL belongs in a defensive/income sleeve, not the growth or Degen tiers.
CL is not cheap on any lens: 37× trailing GAAP EPS (flattered downward by the Q4 charge — ~26× on Base Business EPS), ~25× FY26E, ~24× FY27E, ~20× FY30E, EV/EBITDA 21×, EV/sales 4.0×, FCF yield ~4.9%, dividend yield ~2.2%. The bull's defense is that this is simply what a fortress staple with 60% gross margins and 0.32 beta costs — a quality premium that rarely compresses. The bear's point is sharper: ~24× forward for ~4% revenue and 5–6% EPS growth is a demanding multiple, and if staples de-rate or growth disappoints, the multiple has more room to fall than rise. A reverse-DCF read: today's ~$95 implies the market is pricing mid-single-digit EPS growth in perpetuity at a premium multiple — reasonable if execution holds, but with little margin for error. Street targets (context): consensus $96, high $102, low $79, median $99.5 — our $92 base FV is slightly below consensus. Not a value buy; a quality-at-a-full-price name where the entry point does most of the work.
Colgate's moat is real and durable: (1) brand and share dominance — 41.1% global toothpaste share and 32.6% manual-toothbrush share, category-leading positions built over a century; (2) distribution scale across 200+ countries with deep emerging-market roots (Latin America, India, Africa) that are hard for challengers to replicate; (3) Hill's pet-nutrition franchise, a science-backed, vet-recommended premium brand with structural growth. The threats: private label (management flagged lower private-label pet-food sales), shifting consumption patterns (including the long-tail question of GLP-1 weight-loss drugs on some consumer categories), commodity/FX volatility, and slow overall category growth.
Peer set (FMP peers, market cap): Kimberly-Clark $38.1B, Church & Dwight $23.4B, Clorox $11.8B, Kenvue $38.1B, Estée Lauder $30.3B, Mondelez $78.2B, Monster Beverage $95.5B, Diageo $45.7B, Kroger $35.7B, Coca-Cola Europacific $47.3B. Against this staples/household cohort CL commands one of the richest quality multiples, justified by its superior margins and share — but leaving little valuation cushion. Its closest structural comp is Kimberly-Clark; its best growth engine (Hill's) competes with Mars/Nestlé in pet nutrition.
- Net sales +2% to +6% (incl. a low-single-digit positive FX impact); organic sales +1% to +4% (incl. the drag from exiting private-label pet food).
- GAAP: gross margin now expected down (vs up previously); advertising up; double-digit GAAP EPS growth (off the charge-depressed 2025 base).
- Base Business (non-GAAP): gross margin now down (vs up previously); low-to-mid-single-digit EPS growth — the cleaner read on underlying earnings power.
- Also expanded the SGPP productivity program: cumulative pretax charges now $350–550M (from $200–300M), targeting ~$200–300M annual pretax savings by end-2028.
- Treat these as management's self-interested framing (half-weight): the tariff-driven gross-margin cut and low-to-mid-single-digit Base EPS growth are the honest tells — this is a low-growth year being managed for consistency.
Thesis tripwires (what would change the call): organic growth slipping below ~1%; gross margin compressing materially further; a multiple re-rating above ~27× (raising downside) or a pullback toward ~$80 (improving the risk/reward toward Buy).
Watch. Colgate-Palmolive is a genuinely world-class business — 41% global toothpaste share, 60% gross margins, ~30% ROIC, a 0.32 beta, and a 60-plus-year dividend-growth record. But the market knows all of that, and at 37× trailing / ~24× forward earnings for ~4% revenue and 5–6% EPS growth, the price already reflects the quality. Our base-case fair value of ~$92 is roughly flat to the current $95, the Street is at Hold, and the stock is technically overbought (RSI 72). There is no expert-conviction signal to override the valuation math. This is a superb company to own for ballast at a better price, not to chase here.
This verdict is logged as a tracked Synthos call as of 2026-07-03 at $95.13.
claim_ids are cited. The verdict is fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we do not invent it where coverage is absent.